On 17 September 2026, the European Data Protection Board (EDPB) published its final guidelines on the interplay between the General…
Read More →
The District of Delaware’s recent decision in Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. demonstrates that the U.S. Supreme…
Read More →
The Edgar Winter Group’s 1972 instrumental track, “Frankenstein,” and Gene Wilder’s “It’s alive!” exclamation in the 1974 Young Frankenstein movie…
Read More →
Our FDA: Drug & Device Team examines the Food and Drug Administration’s (FDA) draft guidance establishing a comprehensive premarket framework…
Read More →
Our June 2026 article “AI, Influencers, and Liability: What Marketing Agencies Need to Know Before Deploying AI Tools,” surveyed the…
Read More →
A small ceramic bowl sits on a coffee table. A soft blue flame flickers above it. Someone reaches for the…
Read More →
For the first 20 years of my career, I asked questions for a living. As a trial lawyer, I wanted…
Read More →
On October 5, 2026, Celltrion USA announced that OMLYCLO® (omalizumab-igec) is commercially available in the United States. OMLYCLO® is the…
Read More →
Recent legislative developments in multiple states have targeted employers’ use of artificial intelligence (“AI”) in employment decisions, reflecting a growing…
Read More →
Connecticut has put AI governance on the examination agenda. On September 22, 2026, the Connecticut Department of Banking (Department) issued…
Read More →